KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Within-trial cost-effectiveness of novel macrophage-regulating treatment on wound healing in patients with diabetic foot ulcers.J Food Drug AnalPMID 40202410PMC120395302025-Mar-310.98未发现恶性肿瘤人群证据。待处理
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.LancetPMID 40086461PMC125558912025-Mar-290.98未发现恶性肿瘤人群证据。待处理
Flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial fibrillation: results of the phase 3 RESTORE-1 trial.EuropacePMID 40132102PMC119925562025-Mar-280.98未发现恶性肿瘤人群证据。待处理
The Effect of Nurse Navigators in Digital Remote Monitoring in Cancer Care: Case Study Using Structural Equation Modeling.J Med Internet ResPMID 40153795PMC119924972025-Mar-280.90The study is a Phase III RCT with drug intervention and reports original results. However, the primary efficacy endpoint is relative dose intensity (a dose-metric), and the analyzed outcomes are toxicity, hospitalization, and emergency visits (safety/clinical endpoints), none of which are time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).待处理
Dronedarone provides effective early rhythm control: post-hoc analysis of the ATHENA trial using EAST-AFNET 4 criteria.EuropacePMID 40295782PMC120372752025-Mar-280.98未发现恶性肿瘤人群证据。待处理
Inebilizumab for Treatment of IgG4-Related Disease.N Engl J MedPMID 39541094无 PMCID2025-Mar-270.98未发现恶性肿瘤人群证据。待处理
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.N Engl J Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39660834无 PMCID2025-Mar-270.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps.N Engl J MedPMID 40106374无 PMCID2025-Mar-270.98未发现恶性肿瘤人群证据。待处理
Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 study.Eur J CancerPMID 39999670无 PMCID2025-Mar-260.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.Eur J CancerPMID 40010134无 PMCID2025-Mar-260.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40010135无 PMCID2025-Mar-260.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Ulinastatin in the treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma: a phase 3 randomized clinical trial.Nat Commun疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:非 KM 图;Fig. 3:非 KM 图。PMID 40122906PMC119309522025-Mar-230.85This is a Phase III randomized clinical trial in oncology (nasopharyngeal carcinoma) with a drug intervention (Ulinastatin) and reports original results on both the primary endpoint (incidence of grade ≥3 RTOM) and key secondary time-to-event efficacy endpoints (OS, LRRFS, DMFS, PFS) at 3 years. The drug is not a generic/biosimilar and is administered in conjunction with standard chemoradiotherapy.无 KM 图
Efficacy and Safety of a Newly Developed Botulinum Toxin A (MBA-P01) in Patients with Moderate-to-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center, Phase III Study with a Subgroup Analysis on Patients with COVID-19.Toxins (Basel)PMID 40278658PMC120311672025-Mar-230.98未发现恶性肿瘤人群证据。待处理
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIG 1.:非 KM 图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG 4.:森林图/亚组分析图。PMID 39591551PMC119364762025-Mar-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Randomized, Phase III Trial of Mixed Formulation of Fosrolapitant and Palonosetron (HR20013) in Preventing Cisplatin-Based Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: PROFIT.J Clin OncolPMID 39621965无 PMCID2025-Mar-200.95The trial is a Phase III randomized study with a drug intervention and reports original results, but its primary and key secondary endpoints are complete response rates (non-vomiting/no rescue) for chemotherapy-induced nausea and vomiting prevention. These are categorical efficacy outcomes, not time-to-event endpoints such as overall survival, progression-free survival, or disease-free survival. There is no indication of Kaplan-Meier analysis or hazard ratios for a time-to-event outcome.待处理
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial.J Clin OncolPMID 39693584无 PMCID2025-Mar-200.95Excluded because the trial compares two non-drug interventions (RFA vs. SBRT) and lacks a drug-containing arm, which is a required criterion for eligibility.待处理
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.J Clin OncolPMID 39693591PMC119364772025-Mar-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma.J Clin OncolPMID 39700442PMC119088872025-Mar-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG A1.:非 KM 图;FIG A2.:非 KM 图。PMID 39772655PMC119364732025-Mar-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults.VaccinePMID 39919447无 PMCID2025-Mar-190.98未发现恶性肿瘤人群证据。待处理
Immune response and safety of the adjuvanted recombinant zoster vaccine in adults 50 years of age and older in India: A randomized phase 3 trial.VaccinePMID 39923547无 PMCID2025-Mar-190.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.J NeurolPMID 40105996PMC119230262025-Mar-190.98未发现恶性肿瘤人群证据。待处理
Sonolysis during carotid endarterectomy: randomised controlled trial.BMJPMID 40107675PMC119211502025-Mar-190.98未发现恶性肿瘤人群证据。待处理
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J).Br J DermatolPMID 39442013无 PMCID2025-Mar-180.98未发现恶性肿瘤人群证据。待处理
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.Br J DermatolPMID 39611771无 PMCID2025-Mar-180.98未发现恶性肿瘤人群证据。待处理
Guselkumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients: results of the phase III randomized placebo-controlled PROTOSTAR study.Br J DermatolPMID 39708367无 PMCID2025-Mar-180.98未发现恶性肿瘤人群证据。待处理
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy.J Am Coll CardiolPMID 40074465无 PMCID2025-Mar-180.98未发现恶性肿瘤人群证据。待处理
Improved HbA1c and Body Weight in GADA-Positive Individuals Treated With Tirzepatide: A Post Hoc Analysis of SURPASS.J Clin Endocrinol MetabPMID 38824910PMC119131032025-Mar-170.98未发现恶性肿瘤人群证据。待处理
Lipid and Glucose Profiles in Pregnant Women With HIV on Tenofovir-based Antiretroviral Therapy.Clin Infect DisPMID 39219495PMC119129632025-Mar-170.98未发现恶性肿瘤人群证据。待处理
Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection.J Infect DisPMID 39302855PMC119117922025-Mar-170.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial.J Clin Endocrinol MetabPMID 39376010PMC119131122025-Mar-170.98未发现恶性肿瘤人群证据。待处理
NivobotulinumtoxinA in the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines in Two Phase 3 Clinical Trials.Aesthet Surg JPMID 39587780PMC119131112025-Mar-170.98未发现恶性肿瘤人群证据。待处理
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.BMC CancerPMID 40098083PMC119162072025-Mar-170.85While the study meets criteria for oncology, human subjects, randomization, Phase III, drug intervention, and original results, it lacks the required time-to-event efficacy endpoint. The primary endpoint is duration of neutropenia, a toxicity measure, not a survival or progression-free survival endpoint. Therefore, it is not eligible for the Kaplan-Meier digitization cohort.待处理
Ten-Year Outcomes of a Phase 3, Multicenter, Randomized Controlled Trial (SHIP0804) With 3-Month Neoadjuvant Androgen Deprivation Prior to 125I-Seed Transperineal Prostate Brachytherapy Followed by Nil Versus 9-Month Adjuvant Hormonal Therapy in Patients With Intermediate-Risk Prostate Cancer.Int J Radiat Oncol Biol Phys疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39551103无 PMCID2025-Mar-150.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.NeuropharmacologyPMID 39708914无 PMCID2025-Mar-150.98未发现恶性肿瘤人群证据。待处理
Bone turnover markers predict changes in bone mineral density in men treated with abaloparatide: results from the abaloparatide for the treatment of men with osteoporosis (ATOM) study.J Bone Miner ResPMID 39791502PMC119097332025-Mar-150.98未发现恶性肿瘤人群证据。待处理
Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.LancetPMID 40023176无 PMCID2025-Mar-150.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.LancetPMID 40037388无 PMCID2025-Mar-150.98未发现恶性肿瘤人群证据。待处理
Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing.Int J Mol Sci疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 other;Figure 2:AI 判定为 other;Figure 3:非 KM 图;Figure 4:非 KM 图;Figure 5:非 KM 图。PMID 40141282PMC119422732025-Mar-140.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Mirikizumab Improves Quality of Life and Work Productivity in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.Am J GastroenterolPMID 40079470PMC122825922025-Mar-130.98未发现恶性肿瘤人群证据。待处理
Radiotherapy quality assurance in the PROTECT trial - a European randomised phase III-trial comparing proton and photon therapy in the treatment of patients with oesophageal cancer.Acta OncolPMID 40079654PMC119318552025-Mar-130.75The record describes the quality assurance programme for a phase III randomized trial in esophageal cancer but does not report any survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes. It is a methodological report on trial conduct, not a clinical efficacy report.待处理
Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA.Toxins (Basel)PMID 40137906PMC119465162025-Mar-120.98未发现恶性肿瘤人群证据。待处理
Negative Pressure Dressings to Prevent Surgical Site Infection After Emergency Laparotomy: The SUNRRISE Randomized Clinical Trial.JAMAPMID 39869330PMC117734042025-Mar-110.98未发现恶性肿瘤人群证据。待处理
Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.JAMAPMID 39908052PMC118001242025-Mar-110.98未发现恶性肿瘤人群证据。待处理
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39923274无 PMCID2025-Mar-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39952149无 PMCID2025-Mar-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.J Clin OncolPMID 39378385PMC118958272025-Mar-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。部分完成
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 3 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:非 KM 图;FIG 3.:非 KM 图。PMID 39752608PMC121246602025-Mar-100.98未发现恶性肿瘤人群证据。无 KM 图
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2.Oncologist疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:AI 判定为 other;Figure 1.:非 KM 图。PMID 40163688PMC119572432025-Mar-100.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。无 KM 图
Dummy run study for outlining and plan quality of intensity-modulated radiotherapy in elderly patients with newly diagnosed glioblastoma: The Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).Radiat OncolPMID 40059195PMC118905252025-Mar-090.95This is a protocol quality assurance (dummy run) report for a randomized phase III trial. It does not report any efficacy outcomes (e.g., survival, progression) required for eligibility. Therefore, it is excluded.待处理